SCHEMBL9718762

SCHEMBL9718762

O=C(O)CCN1CCC(=C2c3ccccc3C=Cc3ccccc32)CC1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SETD7 Q8WTS6 4/20 0.61
HTT P42858 2/20 0.57
TSHR P16473 2/20 0.57
DRD2 P14416 2/20 0.57
DRD3 P35462 2/20 0.57
ALDH1A1 P00352 2/20 0.57
ABCB11 O95342 1/20 0.57
TP53 P04637 1/20 0.57
CYP1A2 P05177 1/20 0.57
CHRM2 P08172 1/20 0.57
CHRM4 P08173 1/20 0.57
HTR1A P08908 1/20 0.57
CHRM5 P08912 1/20 0.57
ADRA2A P08913 1/20 0.57
CYP2D6 P10635 1/20 0.57
CHRM1 P11229 1/20 0.57
ADRA2B P18089 1/20 0.57
ADRA2C P18825 1/20 0.57
CHRM3 P20309 1/20 0.57
DRD1 P21728 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9718783 0.92 SETD7 (0.64) SETD7HTTTSHRDRD2DRD3
SCHEMBL9718842 0.91 SETD7 (0.67) SETD7HTTTSHRDRD2DRD3
Hydrochloric Acid SCHEMBL9718733 0.91 SETD7 (0.63) SETD7HTTTSHRDRD2DRD3
Hydrochloric Acid SCHEMBL9718711 0.90 SETD7 (0.65) SETD7HTTTSHRDRD2DRD3
SCHEMBL9718779 0.90 SETD7 (0.69) SETD7HTTTSHRDRD2DRD3
Hydrochloric Acid SCHEMBL9718820 0.89 SETD7 (0.67) SETD7HTTTSHRDRD2DRD3
SCHEMBL9035949 0.88 SETD7 (0.57) SETD7HTTTSHRDRD2DRD3
SCHEMBL11602777 0.88 SETD7 (0.63) SETD7HTTTSHRDRD2DRD3
Hydrochloric Acid SCHEMBL7218913 0.87 KMT2A (0.57) SETD7HTTTSHRDRD2DRD3
Cyproheptadine SCHEMBL28558544 0.86 SETD7 (0.75) SETD7HTTTSHRDRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5095022-A Antiallergens HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1992-03-10 US claimed
US-20230133974-A1 HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOF JIANGNAN UNIVERSITY (CN) 2023-05-04 US disclosed
US-20190284303-A1 Hybridoma cell line of secreting cyproheptadine monoclonal antibodies and preparation method thereof JIANGNAN UNIVERSITY 2019-09-19 US disclosed
US-5095022-A Antiallergens HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1992-03-10 US disclosed
EP-0406739-A2 Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same HOKURIKU PHARMACEUTICAL CO., LTD. (JP) 1991-01-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230133974-A1 HYBRIDOMA CELL LINE OF SECRETING CYPROHEPTADINE MONOCLONAL ANTIBODIES AND PREPARATION METHOD THEREOF HRH1, HRH2, HRH3 SETD7 3560/4885HTT 1681/4885TSHR 1946/4885
US-20190284303-A1 Hybridoma cell line of secreting cyproheptadine monoclonal antibodies and preparation method thereof HRH1, HRH2, HRH3 SETD7 3560/4885HTT 1681/4885TSHR 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.